Skystar Bio-Pharmaceutical Reports Q4 EPS of $0.55
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) reported its Q4 diluted EPS at $0.55, versus the consensus of $0.57. SKBI reported its Q4 revenue at $15.8 million, versus the consensus of $14.91 million.
SKBI shares surged 10.04% to $6.03 in after-hours trading.
Read more from Benzinga's Company news.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.